Optimizing local control of high-risk prostate cancers through multimodal treatments.

[Optimizing local control of high-risk prostate cancers through multimodal treatments]. Prog Urol. 2019 Jun;29 Suppl 1:S8-S19 Authors: Latorzeff I Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80 % of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial PSA value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controversial data in the literature. Radical prostatectomy surgery is a therapeutic option that must be performed with extensive lymph node dissection and is often part of a multimodal care sequence. The therapeutic choice, multidisciplinary, depends on the age and co-morbidity of the patient, the prognostic criteria of the pathology and the urinary function of the patient. Current research focuses on optimizing local and distant control of these aggressive forms and incorporates neo-adjuvant or adjuvant chemotherapy and also new hormone therapies. PMID: 31307631 [PubMed - in process]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research

Related Links:

Tansel Cakir, Selcuk Guven, Bahar Muezzinoglu, Cengiz Erol, Mustafa Yucel Boz, Tamer AtaseverUrology Annals 2019 11(4):439-442 While 68Gallium prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA) has demonstrated increasing utility in the evaluation of prostatic carcinoma, it is essential to be aware of false-negative findings. Further subtype analyses of prostate cancer will be helpful in the understanding of the underlying reasons. We herein present a high-grade prostate adenocarcinoma, with metastatic lesions showing high 18F-labeled fluoro-2-deoxyglucose uptake instead of 68Ga-PSMA.
Source: Urology Annals - Category: Urology & Nephrology Authors: Source Type: research
Authors: Li F, Li H, Hou Y Abstract Prostate adenocarcinoma (PRAD) is one of the most common causes of cancer-associated mortality worldwide. Recent evidence has emphasized the role of competitive endogenous RNAs (ceRNA) in prostate cancer. However, the current understanding of the roles that ceRNAs play in survival-associated PRAD remains in its infancy. In the present study, a PRAD-specific ceRNA network was constructed by integrating long non-coding RNA (lncRNA)-microRNA (miRNA)-gene interactions using experimental and computational methods, as well as expression correlations from The Cancer Genome Atlas databas...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
We report these paired primary epithelial cultures under CRC growth as a potentially useful tool for studies to understand molecular mechanisms underlying health disparities in prostate cancer. PMID: 31576543 [PubMed - in process]
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Cancers, Vol. 11, Pages 1486: Migration and Invasion Enhancer 1 Is an NF-ĸB-Inducing Gene Enhancing the Cell Proliferation and Invasion Ability of Human Prostate Carcinoma Cells In Vitro and In Vivo Cancers doi: 10.3390/cancers11101486 Authors: Chang Tsui Lin Hou Feng Juang : Migration and invasion enhancer 1 (MIEN1) is a membrane-anchored protein and exists in various cancerous tissues. However, the roles of MIEN1 in prostate cancer have not yet been clearly addressed. We determined the expression, biological functions, and regulatory mechanisms of MIEN1 in the prostate. The results of immunohisto...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Contributors : Job van Riet ; Wilbert Zwart ; Yanyun Zhu ; Harmen van de WerkenSeries Type : Genome binding/occupancy profiling by high throughput sequencing ; Third-party reanalysisOrganism : Homo sapiensSupporting ChIP-Seq data for the article "The genomic landscape of metastatic castration-resistant prostate cancers" by Dessel et al. (Nat. Comm. 2019) reveals multiple distinct genotypes with potential clinical impact
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Third-party reanalysis Homo sapiens Source Type: research
ConclusionsSIPA1 may act as a targeting molecule and a marker for prognosis in lung adenocarcinoma. It has an effect on pathways associated with aggressive behavior and barrier function in lung cancer cells. HGF induced malignant behavior of cancer cells requires the presence and influence of SIPA1, which can effect changes in cancer cell behavior by interacting with the TJ complex.Legal entity responsible for the studyTracey A. Martin - Cardiff China Medical Research Collaborative, School of Medicine, Cardiff University.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Authors: Chen D, Fan N, Mo J, Wang W, Wang R, Chen Y, Hu J, Wen Z Abstract Background: Patients with esophageal cancer (EC) frequently have multiple primary cancers. We conducted the present study to assess the risk of multiple primary malignancies for patients with squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the esophagus and to investigate the influence of multiple primary tumors on the prognosis of EC patients. Methods: Using the data of 44,091 EC patients from the Surveillance Epidemiology and End Results (SEER) database, we calculated the standardized incidence ratios (SIRs) for overall multip...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer. Mol Med Rep. 2019 Sep 19;: Authors: Zhou Q, Xiong W, Zhou X, Gao RS, Lin QF, Liu HY, Li JN, Tian XF Abstract Collagen triple helix repeat containing 1 (CTHRC1) is a gene that has been associated with tumor progression in human prostate cancer (PC). The tumor immune microenvironment has been linked with disease outcome in PC. In the present study, the correlation between CTHRC1 with PC recurrence and the tumor immunological microenvironment was investigated. Using the data supplied by the Tumor Immune Estimation Resource ...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Publication date: Available online 21 September 2019Source: Pathology - Research and PracticeAuthor(s): Rahul Mannan, Alexander S. Taylor, Daniel E. Spratt, Arul M. Chinnaiyan, Jeffrey S. Montgomery, Noah A. Brown, Rohit MehraAbstractBladder cancer continues to be a source of disease burden worldwide. In patients with a long-standing history of prostate cancer, distinguishing between new/independent and synchronous poorly differentiated urothelial carcinoma (UCA) and residual/recurrent high grade/poorly differentiated prostatic adenocarcinoma or prostatic adenocarcinoma with therapy-related changes can be diagnostically an...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Cancers, Vol. 11, Pages 1405: Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play Cancers doi: 10.3390/cancers11101405 Authors: Girijesh Kumar Patel Natasha Chugh Manisha Tripathi Our understanding of neuroendocrine prostate cancer (NEPC) has assumed a new perspective in light of the recent advances in research. Although classical NEPC is rarely seen in the clinic, focal neuroendocrine trans-differentiation of prostate adenocarcinoma occurs in about 30% of advanced prostate cancer (PCa) cases, and represents a therapeutic challenge. Even though our knowledge ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Adenocarcinoma | Brachytherapy | Cancer | Cancer & Oncology | Chemistry | Chemotherapy | Hormonal Therapy | Hormones | Pathology | Prostate Cancer | Prostatectomy | Radiation Therapy | Urology & Nephrology